Q BioMed Inc CEO Denis Corin talks to Proactive about its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current pipeline of products and platforms.
Corin says the focus for 2022 is to monetize the current pipeline and build a platform for future growth concentrated on four factors: commercial product revenue growth, partnerships, joint venture equity, value and future development platform.